For Immediate ReleasesChicago, IL – August 6, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Baxter International (BAX) , Henry Schein (HSIC) , and IDEXX Laboratories (IDXX) .Here are highlights from Tuesday’s Analyst Blog:What's in Store for These 3 MedTech Stocks in Q2 Earnings?Medical sector players that have ...

Analysts on Wall Street project that Baxter International (BAX) will announce quarterly earnings of $0.66 per share in its forthcoming report, representing an increase of 20% year over year. Revenues are projected to reach $3.74 billion, increasing 1% from the same quarter last year.Over the last 30 days, there has been a downward revision of 0.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial for ...

Baxter International Inc. (BAX) announced the launch of its Helion Integrated Surgical System in Thailand. This innovative system leverages advanced operating room integration (ORI) to simplify the complexities of surgical environments. By enhancing OR efficiency and enabling surgical teams to stay focused and connected, the Helion system represents a significant advancement in medical technology.The Helion Integrated Surgical System was launched by Hillrom in the U.S. market in 2021. Besides Thailand, the ...

ipopba Healthcare remains one of my favorite sectors to find names that offer growth and income due to the inelastic demand for products and services. The steady nature of many companies in this sector paves the way for a return of capital through share repurchases and dividends. It is the latter of these capital returns that really has my attention when it comes to investing. Baxter International (NYSE:BAX) is a name I have followed in the past, but have never purchased, primarily because the valuation ...

Shares of Baxter International Inc (NYSE:BAX) are down 2.9% at $34.28, after a downgrade from Morgan Stanley to "underweight" from "equal weight," with a price-target cut to $30 from $39. The firm raised concerns over the medical equipment name's margin goals, noting its financial outlook may be more challenging than previously thought, particularly after its acquisition of Hillrom. On the charts, support at the $33 level kept losses in check over the past couple months. However, overhead pressure at the 60 ...

Shares of Baxter International (BAX) have gained 2.4% in the first seven trading sessions in July after declining 13.5% in the first six months of 2024.The decline in BAX’s shares during the first half can be attributed to challenges, including inflationary pressure and weaker ESRD patient volume in China due to the residual impact of COVID-19. Moreover, China’s value-based procurement initiatives are lowering realized price for the company’s products in the country.Meanwhile, the recovery in Baxter’s share ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true v ...

文章核心观点 - 百特国际公司(BAX)近期宣布召回其Life2000呼吸机系统,这是该公司自收购Hillrom以来的一系列召回事件之一,突显了确保这些医疗设备安全性和有效性的持续挑战[1][2][3][4] - Life2000呼吸机系统存在电池充电器故障问题,可能导致呼吸机电池无法充电,给需要呼吸支持的患者带来严重健康后果[3] - 百特公司还曾因其他Hillrom产品如Volara呼吸机系统存在缺陷而进行过召回[7] 行业概况 - 根据MARKETSANDMARKETS的报告,全球呼吸机市场规模预计将从2023年的42亿美元增长到2028年的57亿美元,年复合增长率为6.4%,主要驱动因素包括不健康饮食、肥胖和缺乏运动等导致呼吸疾病负担加重[8] 公司近期动态 - 2023年5月,百特公司获得FDA批准,将其Clinolipid(脂肪注射乳液)的适应症扩大至包括早产儿和足月新生儿在内的儿科患者[9] - 同月,百特公司公布新数据显示,使用Theranova透析器进行的扩展血液透析(HDx疗法)与常规高通量血液透析相比,4年内全因死亡率降低约25%,突出了HDx疗法在长期透析治疗中改善患者预后的潜力[10] 股价表现 - 今年以来,百特公司股价下跌9.7%,而同期医疗行业指数上涨1.8%,标准普尔500指数上涨17.5%[11]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.W ...

Baxter International (BAX) is poised for growth, given the demand for its medically essential products, coupled with transformational actions. However, inflationary pressure remains a concern.Shares of this Zacks Rank #3 (Hold) company have lost 12.4% year to date against the industry's 3.1% growth. The S&P 500 Index has increased 11.6% in the same time frame.BAX, with a market capitalization of $17.27 billion, is a global medical technology company providing items such as kidney-dialysis equipment, infusio ...